Finance

Beta
Lists
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$632.40
+1.98%
(+12.26) 1D
Jun 26, 3:29:57 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for REGN...
Open
$623.64
High
$638.76
Low
$623.44
Mkt. cap
66.28B
Avg. vol.
1.22M
Volume
491.56K
Dividend
0.59%
Quarterly dividend
$0.94
Ex-dividend date
May 20, 2026
P/E ratio
15.41
52-wk high
$821.11
52-wk low
$517.39
EPS
$41.03
Beta
0.25
Shares outstanding
103.02M
No. of employees
15K
Open
$623.64
High
$638.76
Low
$623.44
Mkt. cap
66.28B
Avg. vol.
1.22M
Volume
491.56K
Dividend
0.59%
Quarterly dividend
$0.94
Ex-dividend date
May 20, 2026
P/E ratio
15.41
52-wk high
$821.11
52-wk low
$517.39
EPS
$41.03
Beta
0.25
Shares outstanding
103.02M
No. of employees
15K
News stories
From sources across the web
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com
Analyst ratings
Based on 21 analysts giving stock ratings to REGN in the past 3 months
Buy
Buy
15
Hold
6
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for REGN in the last 3 months.
Highest
Current $632.40
$995.00 (+57.34%)
Average
$826.90 (+30.76%)
Lowest
$641.00 (+1.36%)
Analyst
Recommendation
Action
Price target
Projected
Date
Terence Flynn
Morgan Stanley
Hold
Maintained
$788.00
+24.6%
06/24/2026
Geoff Meacham
Citi
Hold
Maintained
$700.00
+10.7%
06/22/2026
Biren Amin
Piper Sandler
Buy
Maintained
$855.00
+35.2%
06/02/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$730.00
+15.4%
05/21/2026
Louise Chen
Scotiabank
Hold
Maintained
$770.00
+21.8%
05/19/2026
John Newman
Canaccord Genuity
Buy
Maintained
$875.00
+38.4%
05/19/2026
Alexandria Hammond
Wolfe Research
Buy
Reiterated
$860.00
+36%
05/18/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$825.00
+30.5%
05/18/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$968.00
+53.1%
05/18/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$707.00
+11.8%
05/17/2026
Gregory Renza
Truist Financial
Buy
Maintained
$778.00
+23%
05/18/2026
Mohit Bansal
Wells Fargo
Hold
Reiterated
$700.00
+10.7%
05/18/2026
Chris Schott
J.P. Morgan
Buy
Reiterated
$850.00
+34.4%
05/18/2026
David Risinger
Leerink Partners
Hold
Downgraded
$641.00
+1.4%
05/18/2026
Eliana Merle
Barclays
Buy
Maintained
$917.00
+45%
05/18/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$860.00
+36%
05/17/2026
Nicholas Lorusso
TD Cowen
Buy
Maintained
$960.00
+51.8%
05/06/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$995.00
+57.3%
04/30/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$865.00
+36.8%
04/30/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$800.00
+26.5%
04/29/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
$960.00
+51.8%
04/23/2026
William Pickering
Bernstein
Buy
Maintained
$921.00
+45.6%
04/08/2026
Akash Tewari
Jefferies
Buy
Maintained
$890.00
+40.7%
03/11/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
$742.00
+17.3%
02/02/2026
Christopher Raymond
Raymond James
Buy
Maintained
$870.00
+37.6%
01/30/2026
Last report
Apr 29, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$9.47 / $8.90
+6.38%beat
Revenue / Est. (USD)
3.61B / 3.48B
+3.50%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
3.68B
3.75B
3.88B
3.61B
Cost of goods sold
1.95B
2.00B
2.21B
2.21B
Cost of revenue
1.95B
2.00B
2.21B
2.21B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
634.20M
657.80M
775.00M
647.70M
Operating expense
634.20M
647.80M
775.00M
647.70M
Total operating expenses
2.59B
2.64B
2.99B
2.86B
Operating income
1.09B
1.11B
898.60M
744.80M
Other non operating income
18.20M
3.00M
958.50M
-7.30M
EBT including unusual items
1.52B
1.76B
1.04B
831.20M
EBT excluding unusual items
1.28B
1.27B
2.04B
908.10M
Income tax expense
127.10M
303.30M
199.10M
104.00M
Effective tax rate
8.37%
17.20%
19.08%
12.51%
Other operating expenses
-
-10.00M
-
-
Net income
1.39B
1.46B
844.60M
727.20M
Net profit margin
37.86%
38.89%
21.74%
20.17%
Earnings per share
12.89
11.83
11.44
9.47
Interest and investment income
174.80M
175.10M
193.30M
183.50M
Interest expense
-3.60M
-19.30M
-12.20M
-12.90M
Net interest expenses
171.20M
155.80M
181.10M
170.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.22B
1.25B
1.04B
868.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of REGN
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer